Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Caldés, A. (A.) | - |
dc.creator | Colom, H. (H.) | - |
dc.creator | Armendariz, Y. (Y.) | - |
dc.creator | Garrido, M.J. (María Jesús) | - |
dc.creator | Troconiz, I.F. (Iñaki F.) | - |
dc.creator | Gil-Vernet, S. (S.) | - |
dc.creator | Lloberas, N. (N.) | - |
dc.creator | Pou, L. (L.) | - |
dc.creator | Peraire, C. (Concepción) | - |
dc.creator | Grinyó, J.M. (J. M.) | - |
dc.date.accessioned | 2012-04-20T09:49:56Z | - |
dc.date.available | 2012-04-20T09:49:56Z | - |
dc.date.issued | 2009 | - |
dc.identifier.citation | Caldés A, Colom H, Armendariz Y, Garrido MJ, Troconiz IF, Gil-Vernet S, et al. Population Pharmacokinetics of Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in Solid Organ Transplant Patients Infected with Cytomegalovirus. Antimicrob Agents Chemother. 2009 Nov;53(11):4816-24. | es_ES |
dc.identifier.issn | 0066-4804 | - |
dc.identifier.uri | https://hdl.handle.net/10171/21704 | - |
dc.description.abstract | A population pharmacokinetics analysis was performed after intravenous ganciclovir and oral valganciclovir in solid organ transplant patients with cytomegalovirus. Patients received ganciclovir at 5 mg/kg of body weight (5 days) and then 900 mg of valganciclovir (16 days), both twice daily with dose adjustment for renal function. A total of 382 serum concentrations from days 5 and 15 were analyzed with NONMEM VI. Renal function given by creatinine clearance (CL(CR)) was the most influential covariate in CL. The final pharmacokinetic parameters were as follows: ganciclovir clearance (CL) was 7.49.(CL(CR)/57) liter/h (57 was the mean population value of CL(CR)); the central and peripheral distribution volumes were 31.9 liters and 32.0 liters, respectively; intercompartmental clearance was 10.2 liter/h; the first-order absorption rate constant was 0.895 h(-1); bioavailability was 0.825; and lag time was 0.382 h. The CL(CR) was the best predictor of CL, making dose adjustment by this covariate important to achieve the most efficacious ganciclovir exposure. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | American Society for Microbiology | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Pharmacokinetic | es_ES |
dc.subject | Intravenous ganciclovir | es_ES |
dc.subject | Oral valganciclovir | es_ES |
dc.title | Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1128/AAC.00085-09 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.